Extrait

To describe by histology group the adverse event profile, pharmacokinetics (PK) and recommended dose of RO5083945 in combination with cisplatin and gemcitabine/pemetrexed To demonstrate by histology group evidence of superior activity of RO5083945 added to cisplatin and gemcitabine/pemetrexed versus chemotherapy alone in terms of PFS

Critère d'inclusion

• Locally advanced (stage IIIb), metastatic (IV) or recurrent, non-small cell lung cancer who have not received prior chemotherapy

Liens

• ictrp
• euctr
• euctr
• euctr
• ictrp
• ictrp